Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

← catalyst calendar

NCT06307665 · readout in 420 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

440estimated

Sites

150

Countries

China, Mexico, South Africa +1

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-05-20

actual

When the study began enrolling

Primary completion

2027-10-13

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-10-13

estimated

The whole study's end, after follow-up

First posted

2024-03-13

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-13

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Asthma

Interventions

Combination product: BDA MDI — also filed as PT027
Combination product: AS MDI — also filed as PT007

Primary outcome

what the primary-completion date above is the date OF

Annualized rate of severe asthma exacerbations (AAER)

measured From Randomization (Day 1) to Week 52 (EOT)

Publications

PMID 41791845 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed